Takeda Pharmaceutical Company Limited
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-48.0% vs price
Base Case (Median)
-28.2% vs price
Bull Case (75th pct.)
29.5% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $2633.41 | -48.2% | High (40%) |
| PE Comparable | $2654.70 | -47.8% | Medium (25%) |
| Growth Trajectory DCF | $4662.63 | -8.3% | Medium (20%) |
| Graham Number | $3648.45 | -28.2% | Medium (40%) |
| EV/EBITDA | $8500.54 | 67.3% | Medium (20%) |
| EV/FCF | $9934.45 | 95.5% | Medium (20%) |
| Earnings Power Value | $833.25 | -83.6% | Medium (50%) |
Based on 7 out of 8 methods, 4502.T appears fairly valued at the current price of $5082.00. The base case fair value of $3648.45 implies 28.2% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.